Immune checkpoint inhibitors are a relatively new treatment option for patients with metastatic, unresectable head and neck squamous cell carcinoma (HNSCC), and so they have not yet been incorporated into clinical practice guidelines. For this reason, we interview Professor Frederic Peyrade, Head of Clinical Research and Professor of Oncology, Antoine Lacassagne Cancer Centre, France, to get expert advice on incorporating immune checkpoint inhibitors into current treatment protocols.
References
- Grégoire V, et al. Ann Oncol. 2009; 20 Suppl 4: 121-2
- Dimitrios Colevas, et al. J Natl Compr Canc Netw. 2018 May; 16(5): 479-490
- Cohen, et al. J Immunother Cancer. 2019 Jul 15; 7(1): 184
Access more free education today! Visit the website, follow us on Twitter (@onckip) or connect on LinkedIn.
This independent educational activity is supported by an educational grant from Merck, Sharpe & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; MSD corp. has had no influence on the content of this education.